ERGO Nandrolone phenylpropionate 100mg/ml 10ml
Nandrolone phenylpropionate is an injectable form of the anabolic steroid nandrolone. Nandrolone decanoate provides a release of nandrolone from the area of injection lasting approximately 3 weeks, nandrolone phenylpropionate is active for only about a week. In clinical situations. Nandrolone phenylpropionate is valued by athletes and bodybuilders for its abilities to promote strength and lean muscle mass gains without significant estrogenic or androgenic side effects.
Nandrolone Phenylpropionate is a 19-nortestosterone (19-nor) anabolic androgenic steroid. The 19-nor classification refers to a structural change of the testosterone hormone in that the carbon atom has been removed at the 19th position. This simple structural change gives us Nandrolone, and by adding the short Phenylpropionate ester we have Nandrolone Phenylpropionate. On the basis of the hormone’s function, Nandrolone Phenylpropionate is identical to Nandrolone Decanoate. Both forms are comprised of the same active hormone. In the case of NPP we have a shorter ester version that gives a larger burst of Nandrolone after injection, but also carries a much shorter decay half-life. This means Nandrolone Phenylpropionate has to be injected more frequently than its larger ester counterpart if blood levels are meant
to remain stable.
Indications and Usage
Osteoporosis, catabolic states, renal insufficiency to counteract glucocorticoid, suboptimal growth in children, hypoplastic, hemolytic or malignancy associated anaemia, to enhance physical ability in athletes, chronic debilitating diseases especially in elderly patients to correct defective protein metabolism.
The usual dosage for physique- or performance enhancing purposes is in the range of 200-400 mg per week, taken in cycles lasting 8 to 12 weeks. This level is sufficient for the most users to notice measurable gains in lean muscle mass and strength.
Hypercalcemia may develop spontaneously as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the usage of the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic diseases.
– Male patients with carcinoma of the breast or with known or suspected prostate
– Carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones.
– Pregnancy, because of masculinization of the fetus.
– Nephrosis or the nephrotic phase of nephritis
Cholestatic jaundice is associated with therapeutic use of the anabolic and the androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of corticosteroids, ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child is, the greater the risk of compromising final mature height might be. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.
Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be adjusted in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring, especially when starting or stopping taking anabolic steroids.
Hepatic Hepatocellular neoplasms have been reported in association with long-term androgenic anabolic steroid therapy.
Prepubertal: Phallic enlargement and increased frequency of erections.
Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritation.
Clitoral enlargement, menstrual irregularities.
In both genders: Increased or decreased libido.
CNS: Habituation, excitation, insomnia, depression.
Gastrointestinal: Nausea, vomiting, diarrhea.
Hematologic: Bleeding in patients on concomitant anticoagulant therapy
Larynx: Deepening of the voice in women.
Hair: Hirsutism and male pattern of baldness in women.
Skin: Acne (especially in women and prepubertal boys.)
Fluid and Electrolytes: Edema, retention of serum electrolytes (sodium, chloride, potassium, phosphate, calcium). Metabolic/Endocrine: Decreased glucose tolerance, increased serum levels of low-density lipoprotein and decreased levels of high-density lipoprotein, increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK).
Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens.
There have been no reports of acute overdosing with this substance. Symptomatic treatment should be provided.
Store in a dark, dry place. Keep away from children.
1x10ml glass vial